Crowley Wealth Management Inc. Has $208,000 Holdings in Nuvation Bio Inc. $NUVB

Key Points

• Crowley Wealth Management Inc. increased its holdings in Nuvation Bio Inc. by 1,425.7% in Q2, owning 106,798 shares valued at $208,000 as per its latest filing.
• Nuvation Bio's stock recently declined by 7.3%, opening at $3.01, with a market cap of $1.03 billion.
• Analysts maintain a positive outlook for Nuvation Bio, with a consensus target price of $7.50 and several firms rating the stock as "outperform."

Crowley Wealth Management Inc. grew its position in shares of Nuvation Bio Inc. (NYSE:NUVB - Free Report) by 1,425.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 106,798 shares of the company's stock after acquiring an additional 99,798 shares during the quarter. Crowley Wealth Management Inc.'s holdings in Nuvation Bio were worth $208,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of NUVB. BNP Paribas Financial Markets acquired a new stake in Nuvation Bio in the 4th quarter valued at $64,000. Deutsche Bank AG raised its holdings in Nuvation Bio by 58.0% during the fourth quarter. Deutsche Bank AG now owns 155,100 shares of the company's stock worth $413,000 after buying an additional 56,931 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Nuvation Bio by 5.8% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 103,939 shares of the company's stock valued at $276,000 after buying an additional 5,693 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Nuvation Bio by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 51,060 shares of the company's stock worth $136,000 after acquiring an additional 16,801 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Nuvation Bio by 0.5% in the 4th quarter. Two Sigma Investments LP now owns 1,151,256 shares of the company's stock valued at $3,062,000 after acquiring an additional 5,925 shares in the last quarter. 61.67% of the stock is owned by institutional investors and hedge funds.

Nuvation Bio Stock Down 7.3%

Shares of NYSE:NUVB opened at $3.01 on Friday. The company has a market capitalization of $1.03 billion, a PE ratio of -4.77 and a beta of 1.36. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.39 and a quick ratio of 9.38. The business has a fifty day moving average price of $2.83 and a two-hundred day moving average price of $2.33. Nuvation Bio Inc. has a 1 year low of $1.54 and a 1 year high of $4.09.

Nuvation Bio (NYSE:NUVB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.17) EPS for the quarter, hitting analysts' consensus estimates of ($0.17). The company had revenue of $4.83 million for the quarter, compared to analysts' expectations of $0.42 million. Nuvation Bio had a negative return on equity of 46.14% and a negative net margin of 1,413.43%. Analysts forecast that Nuvation Bio Inc. will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NUVB. Royal Bank Of Canada boosted their price objective on Nuvation Bio from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. JMP Securities reiterated a "market outperform" rating and set a $6.00 price target on shares of Nuvation Bio in a report on Wednesday, June 25th. Wall Street Zen raised Nuvation Bio from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Wedbush reaffirmed an "outperform" rating and set a $6.00 price objective on shares of Nuvation Bio in a report on Monday, September 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Nuvation Bio in a report on Friday, September 19th. One investment analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to MarketBeat, Nuvation Bio presently has an average rating of "Buy" and a consensus target price of $7.50.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

Want to see what other hedge funds are holding NUVB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvation Bio Inc. (NYSE:NUVB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.